Survodutide
An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.
What is Survodutide?
Survodutide is an investigational dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for global development and commercialization. The molecule is derived from the natural gut hormone oxyntomodulin and activates both the glucagon and GLP-1 receptors. On April 28, 2026, Boehringer announced positive Phase 3 SYNCHRONIZE-1 topline results: in 725 adults with obesity or overweight without type 2 diabetes, 76 weeks of weekly subcutaneous survodutide (3.6 mg or 6.0 mg) produced a 16.6% mean weight loss versus 3.2% on placebo (efficacy estimand, p<0.0001), with 85.1% of treated participants achieving at least 5% body-weight reduction versus 38.8% on placebo. Both co-primary endpoints were met under both efficacy and treatment-regimen estimands, and the key secondary endpoint of waist-circumference reduction was statistically significant. Initial body-composition analysis indicated that the weight loss was predominantly fat, with lean mass contributing only a small proportion. Survodutide carries FDA Fast Track designation (May 2021) and Breakthrough Therapy designation (September 2024) for non-cirrhotic MASH with stage 2 or 3 fibrosis, EMA PRIME scheme acceptance (November 2023), and Breakthrough Therapy designations from China's NMPA (June 2024) and Taiwan FDA (September 2024). It is not yet approved by any regulator. Full SYNCHRONIZE-1 data are scheduled for the American Diabetes Association 2026 Scientific Sessions in June 2026, with additional Phase 3 readouts (SYNCHRONIZE-2 in T2D, SYNCHRONIZE-MASLD, SYNCHRONIZE-CVOT, SYNCHRONIZE-JP, SYNCHRONIZE-CN) and the LIVERAGE / LIVERAGE-Cirrhosis MASH trials expected through 2026–2027.
What Survodutide Is Investigated For
Survodutide is being developed for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), and as of April 28, 2026 the strongest evidence is the just-announced Phase 3 SYNCHRONIZE-1 topline: 725 adults with obesity or overweight without type 2 diabetes, treated with weekly subcutaneous survodutide at 3.6 mg or 6.0 mg for 76 weeks, achieved 16.6% mean weight loss versus 3.2% on placebo (efficacy estimand, p<0.0001), with 85.1% of treated participants reaching at least 5% body-weight reduction versus 38.8% on placebo, and a statistically significant reduction in waist circumference. Both co-primary endpoints were met under both efficacy and treatment-regimen estimands, and initial body-composition analysis indicated the loss was predominantly fat. Phase 2 evidence remains foundational: 14.9% mean (up to 18.7% in completers) at 46 weeks on 4.8 mg weekly in obesity, and 62% MASH resolution / 36% fibrosis improvement at 4.8 mg over 48 weeks in the Phase 2 NEJM MASH trial — among the highest histologic response rates reported for any incretin-class drug. Honest caveats remain. The 16.6% headline number is a topline press-release figure pending peer-reviewed publication and ADA 2026 presentation; full safety, tolerability, and per-dose breakdowns will follow. SYNCHRONIZE-2 (T2D), SYNCHRONIZE-MASLD, SYNCHRONIZE-CVOT, SYNCHRONIZE-JP, and SYNCHRONIZE-CN are still in follow-up, and the LIVERAGE and LIVERAGE-Cirrhosis Phase 3 MASH trials are enrolling. No head-to-head data versus tirzepatide, semaglutide, or retatrutide exist. The Phase 3 GI tolerability signal — described in the SYNCHRONIZE-1 announcement as mild-to-moderate, temporary, and concentrated during dose escalation, with 'no new safety concerns' beyond GLP-1 class effects — looks better than the ~25% discontinuation rate seen at top doses in Phase 2, but the formal numbers will need to be examined when the full data publish.
History & Discovery
Survodutide (BI 456906) originated as a Zealand Pharma peptide engineered on an oxyntomodulin backbone — oxyntomodulin is a naturally occurring post-translational product of the proglucagon gene that intrinsically activates both the GLP-1 and glucagon receptors, and it has been the starting point for several modern dual-agonist programs. Zealand partnered the molecule with Boehringer Ingelheim in 2011, and Boehringer took operational control of clinical development while Zealand retained royalty rights. Early Phase 1 and Phase 2 work through the late 2010s and early 2020s established dose-dependent weight loss and a distinctive liver-targeted efficacy signal that distinguished it from pure GLP-1 agonists. The 2024 Phase 2 readouts in Lancet Diabetes & Endocrinology (obesity) and the New England Journal of Medicine (MASH/fibrosis) substantially raised the molecule's profile, positioning it as a serious late-stage contender in the incretin class. Regulatory recognition for the MASH indication accumulated through the early 2020s: the FDA granted Fast Track designation in May 2021, the EMA admitted survodutide to its PRIME scheme in November 2023, and three additional regulators awarded Breakthrough-class designations in 2024 — China's NMPA in June 2024, the U.S. FDA in September 2024, and Taiwan's FDA in September 2024. These designations marked survodutide as a serious MASH contender alongside the broader incretin class. The inflection point for the obesity indication arrived on April 28, 2026, when Boehringer Ingelheim announced positive Phase 3 SYNCHRONIZE-1 topline results. In 725 adults with obesity or overweight without type 2 diabetes, weekly subcutaneous survodutide at 3.6 mg or 6.0 mg for 76 weeks produced 16.6% mean weight loss versus 3.2% on placebo (efficacy estimand, p<0.0001), with 85.1% of treated participants reaching at least 5% body-weight reduction versus 38.8% on placebo. Both co-primary endpoints were met under both the efficacy and treatment-regimen estimands, and the key secondary endpoint of waist-circumference reduction was statistically significant. Initial body-composition analysis indicated the weight loss was predominantly fat. Full data are scheduled for the American Diabetes Association 2026 Scientific Sessions in June 2026. The SYNCHRONIZE program is now broader than originally announced. Beyond SYNCHRONIZE-1 and the previously described SYNCHRONIZE-2 (obesity with T2D) and SYNCHRONIZE-CVOT (cardiovascular outcomes, baseline characteristics published in JACC Heart Failure November 2025), Boehringer is running SYNCHRONIZE-MASLD (obesity with confirmed or presumed MASH), SYNCHRONIZE-JP (Japan), and SYNCHRONIZE-CN (China). In parallel, the Phase 3 MASH-specific program comprises LIVERAGE (~1,800 adults with MASH and stage 2 or 3 fibrosis, NCT06632444) and LIVERAGE-Cirrhosis (~1,590 adults with compensated MASH cirrhosis, fibrosis stage 4, NCT06632457). A 2026 Molecular Metabolism paper extended the mechanistic story by showing that survodutide acts through circumventricular organs in the brain to activate neuronal regions associated with appetite regulation, reinforcing that the GLP-1 arm of the dual mechanism reaches central feeding circuits. Recent network meta-analyses have begun positioning survodutide and other GCGR agonists comparatively against pure GLP-1s and against the MASH-specific therapy resmetirom, though the definitive head-to-head comparisons against tirzepatide, retatrutide, and semaglutide await dedicated trials. Beyond survodutide, Boehringer has signaled a broader metabolic-health pipeline including a triple GLP-1/GIP/NPY2 receptor agonist peptide (BI 3034701) entering Phase 2 in mid-2026.
How It Works
Survodutide activates two hormone receptors simultaneously: GLP-1 receptors reduce appetite and slow gastric emptying, while glucagon receptors tell your liver to burn more fat and increase overall energy expenditure. This two-pronged approach produces both weight loss and direct liver fat reduction.
Survodutide is a synthetic, long-acting unimolecular peptide derived from oxyntomodulin with dual agonist activity at GCGR and GLP-1R (EC50 ~8 nM and ~1 nM respectively, indicating greater potency at GLP-1R). GLP-1R activation suppresses appetite through hypothalamic and brainstem circuits and slows gastric emptying. GCGR activation increases hepatic fatty acid oxidation, energy expenditure, and thermogenesis while directly reducing hepatic steatosis. The glucagon-mediated liver effects are particularly significant for MASH, where survodutide achieved histologic improvement in fibrosis and steatohepatitis resolution rates substantially exceeding placebo. The complementary mechanisms — reduced energy intake via GLP-1 plus increased energy expenditure and hepatic fat clearance via glucagon — may produce superior metabolic outcomes relative to GLP-1 mono-agonists.
Evidence Snapshot
Human Clinical Evidence
Substantial and accelerating. Phase 3 SYNCHRONIZE-1 topline (April 28, 2026) showed 16.6% mean weight loss at 76 weeks vs 3.2% placebo in 725 adults without T2D — both co-primary endpoints met. Phase 2 obesity (14.9% at 46 weeks) and Phase 2 NEJM MASH (62% MASH resolution) underpin the program. Five additional SYNCHRONIZE Phase 3 trials and two LIVERAGE Phase 3 MASH trials are still reading out. Full SYNCHRONIZE-1 data scheduled for ADA June 2026. Not yet approved by any regulator; FDA Breakthrough Therapy designation for MASH (2024).
Animal / Preclinical
Strong. Dual GCGR/GLP-1R agonism concept well-supported in preclinical models showing additive effects on weight loss, energy expenditure, and hepatic fat reduction. A 2026 Molecular Metabolism paper extended the picture to circumventricular-organ neuroanatomy of appetite regulation.
Mechanistic Rationale
Strong. Both receptor pathways are individually well-characterized. Glucagon's hepatic effects and GLP-1's appetite suppression are complementary and non-overlapping.
Research Gaps & Open Questions
What the current literature has not yet settled about Survodutide:
- 01Phase 3 efficacy and safety readouts — SYNCHRONIZE-1 and SYNCHRONIZE-2 are still enrolling or in follow-up as of the site's current revision, and head-to-head weight loss vs. tirzepatide and CagriSema has not been formally tested.
- 02Cardiovascular outcomes — SYNCHRONIZE-CVOT is designed to test MACE reduction; until it reports, survodutide's cardiovascular profile is inferred from class effects rather than directly established.
- 03Durable MASH and fibrosis outcomes — Phase 2 demonstrated 48-week histologic improvement, but long-term effects on fibrosis progression, cirrhosis risk, and hepatic decompensation require extended follow-up that has not yet been reported.
- 04Optimal patient selection — whether survodutide's dual mechanism confers specific advantage in patients with high liver fat, high baseline BMI, or metabolic syndrome relative to GLP-1-only agents is not yet established.
- 05Tolerability versus efficacy trade-off — the higher GI discontinuation rate observed in Phase 2 (~25% at top dose) needs Phase 3 confirmation with the refined titration schedules being tested.
- 06Long-term effects of chronic glucagon-receptor agonism on hepatic glucose output, cardiac muscle, and blood pressure — areas where glucagon biology has historically raised questions that pure GLP-1s avoid.
Forms & Administration
Weekly SC injection. Phase 2 doses: 0.6-4.8mg weekly (obesity); 2.4-6.0mg weekly (MASH). Phase 3 testing doses up to 3.6mg and 6.0mg weekly. Dose titration protocol with 20-24 week escalation phase. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Phase 2 in obesity (n=387) tested 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg weekly by SC injection, with the 4.8 mg dose producing the largest weight loss (~14.9% treatment-policy, up to 18.7% in completers). Phase 2 in MASH tested 2.4 mg, 4.8 mg, and 6.0 mg weekly. Phase 3 SYNCHRONIZE-1 (the trial that read out positive topline on April 28, 2026 with 16.6% mean weight loss at 76 weeks) tested maintenance doses of 3.6 mg and 6.0 mg weekly versus placebo. The LIVERAGE and LIVERAGE-Cirrhosis Phase 3 MASH trials test up to 6 mg weekly. No FDA-labeled dose exists because survodutide is investigational.
Frequency
Once-weekly subcutaneous injection in all completed and ongoing trials. Boehringer Ingelheim has publicly discussed the potential for less-frequent dosing in future development, but all trial protocols to date have used a weekly cadence.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Survodutide, like other incretin-class obesity and MASH agents, is being developed for indefinite chronic use rather than cyclic administration. Phase 2 exposure ran 46 weeks for obesity and 48 weeks for MASH; Phase 3 trials run 76 weeks. Sustained effect is expected to require continued dosing, consistent with the rest of the GLP-1/glucagon class.
Protocol Notes
Survodutide uses a lengthy dose-escalation schedule — roughly 20–24 weeks to reach the 3.6 mg or 6.0 mg maintenance dose — driven by the fact that adding glucagon-receptor agonism on top of GLP-1 agonism appears to amplify early GI symptoms, particularly nausea and vomiting. In Phase 2, approximately 25% of participants discontinued due to adverse events in the highest-dose arms, a somewhat higher discontinuation rate than what has been observed with pure GLP-1 agonists at comparable efficacy. The glucagon component also has implications for glucose handling that differ from GLP-1-only drugs: glucagon tends to raise hepatic glucose output, which in the context of dual agonism is offset by GLP-1's insulinotropic effect, but the net glycemic profile in specific patient populations — particularly lean or older patients with T2D — is still being characterized in SYNCHRONIZE-2.
Survodutide is not FDA-approved for any indication as of the site's current revision. The doses and schedules above reflect published trial protocols and are not prescriptions. Any access outside of enrollment in a registered clinical trial is not legitimate as of this date.
Timeline of Effects
Onset
In Phase 2, separation from placebo on weight loss became visible within the first 4–8 weeks of titration, with the steepest weight-loss slope occurring during weeks 8–32 as participants reached the maintenance dose. Appetite suppression and early satiety are typically reported within days of dose escalations — consistent with the GLP-1 arm of the mechanism — while the glucagon-mediated increase in energy expenditure and hepatic fat oxidation is harder to perceive subjectively.
Peak Effect
Phase 3 SYNCHRONIZE-1 topline (April 28, 2026): mean weight loss of 16.6% at 76 weeks on 3.6 mg or 6.0 mg weekly (efficacy estimand) versus 3.2% on placebo, with 85.1% of treated participants reaching at least 5% body-weight reduction. Phase 2 obesity reached approximately 14.9% at 46 weeks on 4.8 mg weekly with completers at 18.7%, and the SYNCHRONIZE-1 76-week readout extends that trajectory consistent with the longer follow-up. In the MASH Phase 2, histologic improvement on biopsy was measured at 48 weeks; MASH resolution without worsening fibrosis reached 62% at 4.8 mg vs. 14% on placebo. Whether survodutide matches or extends beyond tirzepatide on weight remains a question for head-to-head trials that have not yet been run, and whether it becomes a first-line MASH therapy is the question LIVERAGE Phase 3 is designed to answer.
After Discontinuation
Direct discontinuation data in humans is limited because the Phase 2 program did not include a formal post-treatment observation arm. By analogy to other incretin agonists, the expectation is significant weight regain within 6–12 months of stopping, reflecting both drug clearance and the underlying biology of obesity as a chronic condition. Liver-fat reduction achieved during treatment would also be expected to recede without continued therapy, though long-term histologic follow-up after stopping has not been published.
Common Questions
Who Survodutide Is NOT For
- •Personal or family history of medullary thyroid carcinoma (MTC) — applied by analogy to the rest of the GLP-1 class given the rodent C-cell tumor signal observed across incretin agonists; exclusion criterion in SYNCHRONIZE.
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — same rationale as MTC.
- •Pregnancy and breastfeeding — no human reproductive toxicity data; animal data prompts exclusion in trials, and the drug's long half-life means washout requires weeks.
- •Type 1 diabetes — the glucagon-receptor component introduces unpredictable hepatic glucose output effects that have not been characterized in insulin-dependent patients; trial exclusion criterion.
- •Significant hepatic decompensation (Child-Pugh C cirrhosis) — despite MASH being a target indication, advanced cirrhosis has been excluded from Phase 2/3 programs pending dedicated safety data.
- •History of severe pancreatitis — applied by analogy to the GLP-1 class pending dedicated survodutide pharmacovigilance.
- •Severe gastroparesis or other major gastrointestinal motility disorders — GLP-1-mediated delayed gastric emptying amplified by glucagon-receptor activation can worsen these conditions.
Drug & Supplement Interactions
No FDA-labeled drug interaction profile exists for survodutide because the drug is not approved. The interaction framework is therefore extrapolated from the GLP-1 and glucagon classes. The two most clinically relevant domains are hypoglycemia risk when combined with insulin or sulfonylureas — where downward titration of the concomitant agent will almost certainly be required if survodutide reaches market — and altered oral drug absorption secondary to delayed gastric emptying, which applies to narrow-therapeutic-index agents including warfarin, levothyroxine, and oral antiepileptics. The glucagon-receptor component adds a theoretical layer not present with pure GLP-1s: glucagon raises hepatic glucose output, which could interact with concomitant antidiabetic regimens in ways distinct from semaglutide or tirzepatide. How this translates clinically in Phase 3 populations — particularly older patients with T2D on complex regimens — is an active area of SYNCHRONIZE-2 analysis.
Safety Profile
Common Side Effects
Cautions
- • Not yet FDA-approved
- • Phase 3 data still pending
- • Gastrointestinal side effects led to discontinuation in ~25% of participants in Phase 2
- • Glucagon component may affect blood sugar regulation differently than GLP-1-only drugs
- • Long-term safety unknown
What We Don't Know
Phase 3 efficacy and safety results, cardiovascular outcomes, long-term tolerability, and optimal dosing are still being determined. The higher GI discontinuation rate relative to some GLP-1-only drugs needs monitoring in Phase 3.
Legal Status
United States
Survodutide is not FDA-approved for any indication as of the site's current revision. The FDA has granted Fast Track designation (May 2021) and Breakthrough Therapy designation (September 2024) for the indication of non-cirrhotic MASH with stage 2 or 3 fibrosis — both are accelerated-development mechanisms, not approvals. Phase 3 SYNCHRONIZE-1 (obesity without T2D) achieved positive topline results on April 28, 2026 with 16.6% mean weight loss at 76 weeks; full data are scheduled for ADA June 2026. Realistic FDA approval timeline for the obesity indication is 2027–2028 pending SYNCHRONIZE-2 and additional Phase 3 readouts. Access is currently limited to participants in Boehringer Ingelheim's Phase 3 program or related registered trials; survodutide is not available through compounding pharmacies, is not legally marketed, and any product sold outside registered trials claiming to be survodutide should be presumed unverified research chemical.
International
No regulatory authority has authorized survodutide for marketing as of April 2026. Regulatory recognition of MASH potential is broader: EMA admitted survodutide to its PRIME scheme in November 2023, China's NMPA granted Breakthrough Therapy designation in June 2024, and Taiwan's FDA granted Breakthrough designation in September 2024. Phase 3 trial sites span the EU, UK, North America, Japan (SYNCHRONIZE-JP), China (SYNCHRONIZE-CN), and other regions, but access remains investigational worldwide.
Sports & Competition
Survodutide is not named on the WADA Prohibited List as of the site's current revision, but WADA's S0 category prohibits substances 'not currently approved by any governmental regulatory health authority for human therapeutic use' — which applies to survodutide. Athletes subject to WADA, USADA, UKAD, or equivalent bodies should assume use is prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Survodutide is available now if you know where to look.
Reality
Survodutide is an investigational agent in active Phase 3 development. Legitimate access is limited to enrollment in Boehringer Ingelheim's SYNCHRONIZE trials or similar registered studies. Research-chemical suppliers advertising 'survodutide' without trial oversight are not selling a pharmaceutical product — the identity, purity, and potency of what's in the vial cannot be assumed, and no regulatory body has authorized the compound for human use.
Myth
Adding glucagon to GLP-1 is obviously better than GLP-1 alone.
Reality
The dual-agonist concept is mechanistically compelling and Phase 2 weight-loss numbers are strong, but head-to-head comparisons against tirzepatide or semaglutide 2.4 mg have not been reported. Cross-trial comparisons — where Phase 2 survodutide is implicitly ranked against Phase 3 tirzepatide — are methodologically weak. The glucagon component also raises the GI-tolerability bar: Phase 2 discontinuation rates ran around 25% in highest-dose arms. Whether survodutide's liver-fat advantage translates into superior real-world outcomes vs. established GLP-1s is a Phase 3 question.
Myth
Because survodutide helps MASH, it's a cure for fatty liver.
Reality
The Phase 2 MASH trial showed MASH resolution in 62% of 4.8 mg participants and fibrosis improvement in 36% at 48 weeks — a striking histologic signal, but still short of 'cure' framing. MASH is a progressive disease with multifactorial drivers; durable outcomes depend on sustained treatment and concurrent lifestyle factors. No approved drug at present — including survodutide, which is still investigational — cures MASH. Pending Phase 3 results, survodutide's most plausible positioning is as a first-line MASH pharmacotherapy alongside weight management, not as a one-time or curative intervention.
Myth
Survodutide is just another GLP-1, so its side effects are the same as Ozempic.
Reality
The GI profile is directionally similar to GLP-1 agonists but appears somewhat more intense in trial data — consistent with dual-receptor pharmacology. Glucagon-receptor activation also introduces considerations that pure GLP-1 agonists don't have, including effects on hepatic glucose output and potential blood pressure and heart-rate signals that Phase 3 is designed to characterize. Treating survodutide's risk profile as a carbon copy of semaglutide's underestimates what's novel about the molecule.
Published Research
20 studiesA review of survodutide: a new dual acting agonist.
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.
Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1)
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis
Meta-analysis of 6 RCTs (n=1,272) confirming survodutide significantly reduces HbA1c, fasting glucagon, and body weight compared to placebo, with higher doses (>2.4mg/week) and longer treatment (>16 weeks) producing greater effects.
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist
Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)
Phase 3 trial design paper describing SYNCHRONIZE-1 (n=726, obesity without T2D) and SYNCHRONIZE-2 (n=755, obesity with T2D), testing survodutide up to 3.6mg and 6.0mg weekly over 76 weeks.
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Pivotal Phase 2 NEJM trial (n=293) demonstrating survodutide achieved MASH resolution without fibrosis worsening in 62% of participants at 4.8mg (vs. 14% placebo), with liver fat reduction of at least 30% in 67%, and fibrosis improvement in 36% at 48 weeks.
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Landmark Phase 2 dose-finding trial (n=387) in Lancet Diabetes Endocrinol showing survodutide achieved up to 14.9% mean weight loss at 46 weeks (4.8mg dose), with completers reaching 18.7%. Over 82% of the highest-dose group lost at least 5% body weight.
SYNCHRONIZE-1 (NCT06066515): A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
LIVERAGE (NCT06632444): A Phase 3 Study to Test Whether Survodutide Helps People With MASH Who Have Moderate or Advanced Liver Fibrosis
LIVERAGE-Cirrhosis (NCT06632457): A Phase 3 Study to Test Whether Survodutide Helps People With MASH Who Have Cirrhosis
Boehringer Ingelheim — SYNCHRONIZE-1 Phase 3 Topline Results (Press Release, April 28, 2026): 16.6% mean weight loss at 76 weeks vs 3.2% placebo
Quick Facts
- Class
- Dual Glucagon/GLP-1 Receptor Agonist
- Tier
- A
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 20PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.